Enrolling by invitationPHASE1, PHASE2NCT07226297
Personalized Antisense Oligonucleotide for A Single Participant With GARS1 Gene Mutation Associated With Charcot-Marie-Tooth Disease Type 2D (CMT2D)
Studying Autosomal dominant Charcot-Marie-Tooth disease type 2D
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- n-Lorem Foundation
- Intervention
- nL-GARS1-001(drug)
- Enrollment
- 1 enrolled
- Eligibility
- 13 years · FEMALE
- Timeline
- 2025 – 2027
Study locations (1)
- UTHealth Houston, Houston, Texas, United States
Collaborators
The University of Texas Health Science Center, Houston
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07226297 on ClinicalTrials.gov